FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1
(programmed death receptor-1) therapy, at a fixed dose of 200 mg every
three weeks, for the treatment of patients with recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC) with disease progression
on or after platinum-containing chemotherap y.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor:Teri Loxam, 908-740-1898orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Food and Drug Administration (FDA) | HNSCC | Merck | Skin Cancer | Squamous Cell Carcinoma